Search papers, labs, and topics across Lattice.
The paper introduces Bayesian Variable Selection-Guided Inductive Matrix Completion (BVSIMC), a Bayesian model that performs variable selection on drug and disease side information to improve drug discovery predictions. BVSIMC learns sparse latent embeddings that enhance both predictive accuracy and interpretability by identifying relevant features. Experiments on drug resistance prediction and drug repositioning demonstrate that BVSIMC outperforms state-of-the-art methods and identifies clinically meaningful features.
Uncover hidden relationships in drug discovery: BVSIMC uses Bayesian variable selection to pinpoint the most relevant chemical and genomic features, boosting prediction accuracy and interpretability.
Recent advances in drug discovery have demonstrated that incorporating side information (e.g., chemical properties about drugs and genomic information about diseases) often greatly improves prediction performance. However, these side features can vary widely in relevance and are often noisy and high-dimensional. We propose Bayesian Variable Selection-Guided Inductive Matrix Completion (BVSIMC), a new Bayesian model that enables variable selection from side features in drug discovery. By learning sparse latent embeddings, BVSIMC improves both predictive accuracy and interpretability. We validate our method through simulation studies and two drug discovery applications: 1) prediction of drug resistance in Mycobacterium tuberculosis, and 2) prediction of new drug-disease associations in computational drug repositioning. On both synthetic and real data, BVSIMC outperforms several other state-of-the-art methods in terms of prediction. In our two real examples, BVSIMC further reveals the most clinically meaningful side features.
